Source:http://linkedlifedata.com/resource/pubmed/id/10360758
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
1999-7-22
|
pubmed:abstractText |
A series of compounds was designed to inhibit human neutrophil elastase utilizing a modified metallopeptide scheme developed in our laboratory termed metal-ion induced distinctive array of structures (MIDAS). These metallopeptides, synthesized by solution and solid-phase methods, exhibited excellent structural diversity and specificity in inhibiting human neutrophil elastase.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0960-894X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
17
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1469-74
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading | |
pubmed:year |
1999
|
pubmed:articleTitle |
Metallopeptide approach to the design of biologically active ligands: design of specific human neutrophil elastase inhibitors.
|
pubmed:affiliation |
Palatin Technologies Inc., Edison Corporate Center, NJ 08837, USA.
|
pubmed:publicationType |
Journal Article
|